Recombinant Human Tropomyosin beta chain (TPM2), partial

^{In
Stock}

中文名稱(chēng)：

人TPM2重組蛋白
品名簡(jiǎn)稱(chēng)：

Recombinant Human TMSB protein, partial
貨號(hào)：

CSB-EP024105HU1
說(shuō)明書(shū)：

MSDS Datasheet
規(guī)格：

￥1344
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

純度：

Greater than 90% as determined by SDS-PAGE.
基因名：

TPM2
Uniprot No.：

P07951
別名：

Alpha tropomyosin; AMCD1; Arthrogryposis multiplex congenital distal type 1; Beta tropomyosin; Beta-tropomyosin; Cytoskeletal tropomyosin TM30; DA1; DA2B; epididymis secretory protein Li 273; FLJ41118; Heat stable cytoskeletal protein 30 kDa; HEL-S-273; hscp30; HTM alpha; hTM5; MGC14582; MGC3261; MGC72094; NEM1; NEM4; Nemaline myopathy type 4; OK/SW cl.5; Sarcomeric tropomyosin kappa; TM 5; TM3; TM30; TM30nm; TMSA; TMSB; TPM 1; TPM 3; TPM1 alpha; TPM1 kappa; TPM2; TPM2_HUMAN; TRK; Tropomyosin 1 alpha; Tropomyosin 1 alpha chain; Tropomyosin 1 alpha chain isoform 6; Tropomyosin 2 (beta); Tropomyosin 2; Tropomyosin 3; Tropomyosin alpha 3 chain; Tropomyosin alpha striated muscle isoform; Tropomyosin beta chain; Tropomyosin gamma; Tropomyosin skeletal muscle beta; Tropomyosin-2
種屬：

Homo sapiens (Human)
蛋白長(zhǎng)度：

Partial
來(lái)源：

E.coli
分子量：

35.3kDa
表達(dá)區(qū)域：

14-284aa
氨基酸序列

DKENAIDRAEQAEADKKQAEDRCKQLEEEQQALQKKLKGTEDEVEKYSESVKEAQEKLEQAEKKATDAEADVASLNRRIQLVEEELDRAQERLATALQKLEEAEKAADESERGMKVIENRAMKDEEKMELQEMQLKEAKHIAEDSDRKYEEVARKLVILEGELERSEERAEVAESKCGDLEEELKIVTNNLKSLEAQADKYSTKEDKYEEEIKLLEEKLKEAETRAEFAERSVAKLEKTIDDLEDEVYAQKMKYKAISEELDNALNDITSL
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標(biāo)簽：

N-terminal 6xHis-tagged
產(chǎn)品提供形式：

Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
儲(chǔ)存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質(zhì)期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

3-7 business days
注意事項(xiàng)：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA：

Please contact us to get it.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Binds to actin filaments in muscle and non-muscle cells. Plays a central role, in association with the troponin complex, in the calcium dependent regulation of vertebrate striated muscle contraction. Smooth muscle contraction is regulated by interaction with caldesmon. In non-muscle cells is implicated in stabilizing cytoskeleton actin filaments. The non-muscle isoform may have a role in agonist-mediated receptor internalization.
基因功能參考文獻(xiàn)：
1. Hypoxia may regulate cell invasiveness partly by TPM2 down-regulation mediated changes of MMP2 expression, which is also a new pathway by which hypoxia regulates cancer progression. TPM2 is a potential novel tumour suppressor gene in breast cancer. PMID: 29414807
2. The increased expression of TPM1lambda and the decreased expression of TPM1delta RNA and TPM2beta may lead to decreased stress fiber formation and malignant transformation in human breast epithelial cells. PMID: 27108600
3. TPM2 appears to be commonly silenced by aberrant DNA methylation in colon cancer. TPM2 loss is associated with RhoA activation and tumor proliferation. PMID: 27333992
4. Despite its reduced affinity for actin in co-sedimentation assay, the Q147P mutant incorporates into the muscle fiber ..Q147P tropomyosin (TPM2)binds to actin in ghost muscle fiber. PMID: 26708479
5. tropomyosin 2.1 acts as a suppressor of growth on soft matrices by supporting proper rigidity sensing PMID: 26619148
6. Myo1c significantly increases the frequency of kinesin-1-driven microtubule-based runs that begin at actin/microtubule intersections. The actin-binding protein tropomyosin 2 abolishes Myo1c-specific effects on both run initiation and run termination. PMID: 25660542
7. Patients with TPM2 mutations tended to present with milder symptoms than those with TPM3 mutations, DA being present only in the TPM2 group. PMID: 24692096
8. in a cohort of 94 patients with congenital myopathy, 2 related female patients and 2 sporadic male patients were found to carry mutations in TPM2 and TPM3 genes respectively; clinical presentation and muscle morphological findings differed in the patients PMID: 24507666
9. Histopathological phenotype association of muscle fibers expressing Beta-tropomyosin mutational variants that occur in human myopathies. PMID: 24039757
10. effect of the skeletal myopathy-causing E117K mutation in human beta-tropomyosin on actomyosin structure during the ATPase cycle PMID: 24657080
11. We showed that TPM2, CLU, and COL4A6 mRNA levels are downregulated in prostate cancer. PMID: 23621580
12. The p.R133W mutation in TPM2 is associated with Sheldon-Hall syndrome. PMID: 23678273
13. The E117K mutation in tropomyosin beta chain that causes nemaline myopathy shifts the tropomyosin strands to the closed position and suppresses their conformational rearrangements on the thin filament. PMID: 23689010
14. expanding the spectrum of TPM2 myopathies to very mild patients who could still be pathologically recognized by the presence of cap structures PMID: 23015096
15. Novel de novo missense mutations in TPM2 were found to be associated with marked fibre size disproportion in two patients with congenital fibre type disproportion. PMID: 22832343
16. The TPM2-null mutations decreased cooperative thin filament activation in combination with reductions in the myosin cross-bridge number and force production PMID: 22798622
17. distal arthrogryposis syndromes associated with TPM2 mutations include the less severe forms[review] PMID: 22749895
18. A novel beta-tropomyosin mutation is described that is associated with two clinical-histopathological phenotypes not previously associated with it. PMID: 23413262
19. p.K7del is a common hetreozygous recurrent TPM2 mutation associated with nemaline myopathy. PMID: 23378224
20. This study demonistrated that most patients with TPM2 mutations show a predominant involvement of masticatory and distal leg muscles with the other regions relatively spared. PMID: 22980765
21. actin binding was weak in three of five mutants suggesting that abnormal binding between actin and aberrant Tm is the pathogenetic mechanism causing muscle weakness in patients with nemaline and cap myopathy. PMID: 22084935
22. in cells expressing R133W beta-tropomyosin mutation, during activation, switching of positive to neutral charge at position 133 partially hinders calcium- and myosin-induced tropomyosin movement over the thin filament blocking actin conformation change PMID: 20457903
23. While demonstrating suppressed levels of Tm1 in the prostate cancer cell lines LNCaP, PC3, and DU-145 compared to normal prostate epithelial cell primary isolates, a novel splice variant of the TPM2 gene was identified. PMID: 20336778
24. Tropomyosin 2 plays a role in growth and metastasis of hepatic tumors. PMID: 18246790
25. beta-tropomyosin exon 6B splicing requires hnRNP A1 and ASF/SF2 and SC35 PMID: 15208309
26. We describe two patients, a woman and her daughter, with muscle weakness and distal arthrogryposis (DA) type 2B, caused by a heterozygous missense mutation, R133W. PMID: 17339586
27. R133W beta-Tm mutation induces alterations in myosin-actin kinetics causing a reduced number of myosin molecules in the strong actin-binding state, resulting in overall muscle weakness in the absence of muscle wasting. PMID: 17430991
28. results indicate that mutations in TPM2 may cause nemaline myopathy as well as cap disease with a dominant mode of inheritance; these disorders may thus be phenotypic variants of the same genetic defect PMID: 17846275
29. beta-TM gene mutations can alter the expression of other sarcomeric TM isoforms PMID: 18422639
30. Mutations in TPM2 seem to be a frequent cause of cap disease. PMID: 19047562
31. This first report of the clinical expression of the complete absence of TPM2 in human indicated that TPM2 expression at the early period of prenatal life plays a major role for normal fetal movements. PMID: 19155175
32. The destabilizing effect of the disease-causing arginine91glycine mutation spreads along the coiled-coil, reflecting the high extent of cooperativity within this part of the beta-tropomyosin molecule. [review] PMID: 19214762
33. Our patient has an identical TPM2 mutation to the first genetically diagnosed cap disease patient, a denovo heterozygous three base pair deletion that removes glutamic acid 139 from the centre of beta-tropomyosin. PMID: 19345583
顯示更多

收起更多
相關(guān)疾病：

Nemaline myopathy 4 (NEM4); Arthrogryposis, distal, 1A (DA1A); Cap myopathy 2 (CAPM2); Arthrogryposis, distal, 2B (DA2B)
亞細(xì)胞定位：

Cytoplasm, cytoskeleton.
蛋白家族：

Tropomyosin family
組織特異性：

Present in primary breast cancer tissue, absent from normal breast tissue.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 12011

OMIM: 108120

KEGG: hsa:7169

STRING: 9606.ENSP00000354219

UniGene: Hs.300772